Tyra Biosciences, Inc. (NASDAQ:TYRA – Get Free Report) shares saw an uptick in trading volume on Monday after HC Wainwright raised their price target on the stock from $30.00 to $32.00. HC Wainwright currently has a buy rating on the stock. 120,491 shares changed hands during trading, a decline of 27% from the previous session’s volume of 165,546 shares.The stock last traded at $21.06 and had previously closed at $21.93.
Other equities research analysts also recently issued research reports about the stock. Oppenheimer upped their price objective on shares of Tyra Biosciences from $25.00 to $33.00 and gave the stock an “outperform” rating in a report on Thursday, September 19th. Bank of America raised shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $22.00 to $31.00 in a report on Friday, October 18th. Wedbush reissued an “outperform” rating and issued a $28.00 price target on shares of Tyra Biosciences in a report on Friday. Finally, Piper Sandler began coverage on shares of Tyra Biosciences in a report on Thursday, August 15th. They issued an “overweight” rating and a $33.00 price target for the company. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $31.40.
View Our Latest Report on Tyra Biosciences
Insider Buying and Selling at Tyra Biosciences
Institutional Trading of Tyra Biosciences
Institutional investors and hedge funds have recently bought and sold shares of the stock. SG Americas Securities LLC acquired a new stake in Tyra Biosciences during the 3rd quarter worth about $311,000. HighVista Strategies LLC acquired a new stake in Tyra Biosciences during the 2nd quarter worth about $257,000. Rhumbline Advisers raised its holdings in Tyra Biosciences by 12.3% during the 2nd quarter. Rhumbline Advisers now owns 23,572 shares of the company’s stock worth $377,000 after buying an additional 2,574 shares during the period. Bank of New York Mellon Corp raised its holdings in Tyra Biosciences by 32.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 58,087 shares of the company’s stock worth $929,000 after buying an additional 14,352 shares during the period. Finally, Oppenheimer & Co. Inc. acquired a new position in shares of Tyra Biosciences in the 1st quarter valued at about $977,000. Institutional investors and hedge funds own 84.14% of the company’s stock.
Tyra Biosciences Trading Down 3.0 %
The company has a market cap of $1.12 billion, a price-to-earnings ratio of -12.98 and a beta of 1.01. The business has a fifty day moving average price of $22.89 and a two-hundred day moving average price of $19.87.
Tyra Biosciences (NASDAQ:TYRA – Get Free Report) last issued its earnings results on Wednesday, August 7th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.09. On average, analysts anticipate that Tyra Biosciences, Inc. will post -1.53 EPS for the current year.
About Tyra Biosciences
Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Featured Articles
- Five stocks we like better than Tyra Biosciences
- When to Sell a Stock for Profit or Loss
- 3 Oil Stocks to Watch Before Earnings Come Out
- 3 Fintech Stocks With Good 2021 Prospects
- Is American Express Stock’s Sell-the-News Reaction a Buying Opp?
- What Does Downgrade Mean in Investing?
- Alphabet’s Earnings Could Surprise—Should You Buy Now?
Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.